Recently, I came across a comprehensive report on RWA published by Messari specifically on Injective. The more I read, the more I felt that this project is genuinely doing solid work, not just relying on storytelling hype, especially a set of data in it that directly boosted my confidence in INJ.
Let me first explain to beginners what RWA is.
RWA refers to bringing real-world assets to the chain for trading, such as stocks and various tangible assets. I used to think this was far from ordinary people, either because the threshold was high or the operations were complex.
But Injective has thoroughly developed this sector. It not only has common on-chain stocks, but it can also trade in the pre-IPO market. Hot companies like OpenAI and SpaceX, which have not yet gone public, can now be participated in by ordinary people through it. This was something I wouldn't have dared to imagine before.
In the past, participating in pre-IPO investments was exclusive to large institutions or wealthy individuals, and small retail investors like us were completely left out.
But Injective has turned these assets into products that can be traded on-chain, also supporting leverage, allowing entry without large amounts of capital. I think this truly makes finance fairer, allowing ordinary people to enjoy the growth dividends of quality assets.
What amazed me the most is its trading data; Injective's RWA perpetual contracts have accumulated a trading volume of $5.5 billion this year, with an annualized income soaring to $6.5 billion.
This figure really shocked me; it is important to note that this is not a small-scale operation. Such a large trading volume indicates that both ordinary users and institutions recognize its RWA ecosystem.
I believe this is largely due to Injective's own advantages; it has fast transaction speeds, no fees, and low market-making costs, making it economical for both frequent trading and long-term holding, naturally attracting more and more users.
Moreover, Messari's report also mentioned that the adoption and usage of Injective in the on-chain finance sector have experienced explosive growth, which I have also felt personally while using it.
In the past, trading products related to real assets on other platforms either had limited categories or complicated processes, and there were often concerns about compliance issues.
However, Injective has a dedicated compliance mechanism that can automatically filter out non-compliant users, meeting regulatory requirements, which gives both individuals and institutions peace of mind, and this is key to attracting so much capital and users.
I think the reason RWA is so popular is that it addresses the pain points of traditional finance.
In the past, many good assets were either unreachable for ordinary people or too slow and expensive to trade. Injective has moved these assets on-chain and provided convenient trading methods, effectively bridging traditional finance and Web3.
Now in its RWA ecosystem, there are already many well-known protocols participating, the types of trading products are continuously increasing, and the more people use it, the more prosperous the ecosystem becomes, forming a virtuous cycle.
For us holders of INJ, these are all tangible benefits.
As the trading volume and revenue of the ecosystem continue to rise, the value of the platform will naturally increase, and INJ, as the native token of the ecosystem, will definitely benefit from it.
I believe Injective has already established a foothold in the RWA track; it has the endorsement of Messari's report and solid data support, so its future development is bound to be promising.
Now the entire industry is focusing on the RWA track, and Injective is already at the forefront, showing impressive performance in product coverage, technical strength, and user growth.
The subsequent stable rise of the INJ token will also have a traceable path, and I have already made plans for long-term holding!
